host srra late session first day
annual jefferi london healthcar confer
held firesid chat w/ ceo discuss recent success w/ fa
alport pivot trial -- co aim move rapidli file note one file
alreadi written would disclos one fa alport
highlight unmet need -- pt current symptom manag data
pbo-control trial fa alport demonstr omav bard respect
could transform pt start convers w/ highlight
omav bard share moa pathway reduc ro shut nfkb-
mediat inflamm alport discuss retained-benefit shown ph iii
co show damag kidney potenti modifi
cours diseas -- show greater benefit vs jynarqu measur
investor ask us egfr declin wk washout -- note
demonstr declin stabil two wk post washout persist
wk confid alport data -- point pbo-
match quartil analysi top-lin updat say even sever pt
still saw improv bard -- disprov treatment effect appar
averag even clear worst-perform quartil note
data go alport file fda would like focu cardin data
ask potenti add indic outsid alport adpkd --
highlight correl w/ efficaci repeat
ph iii alport trial correl help de-risk bard potenti
indic igan fsg assess phoenix ph ii otsuka
jynarqu adpkd note impress w/ launch far note
price reason benchmark adpkd believ like alport
price come much higher given fewer alport pt co
also note limit jynarqu adpkd fa discuss effort
patient advocaci group fara get pt radar registri
believ facilit launch get sens market oppti ask
proxi program rare diseas neurolog space mention spinraza
believ reason analog ask co add indic
fa discuss moxi updat call -- given inflammatori
compon mani neurolog diseas believ omav could find use sever
parallel indic similar bard across rare kidney diseas separ note
kkc ph iii ckd fulli enrol -- rapid enrol w/ pt safeti
updat provid anoth data point support risk-mitig strategi next
nda file fa alport like pdufa date approv clariti
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
adpkd trial enrol timelin data ph iii ctd-pah data
w/ new hdv triple-combo data ph iia lift interim report
ph iii d-livr underway w/ co-guid data view under-valued
also new disclosur -- potenti add prv rare chi indic avexitid --
may miss hdv co recent key interim ph iia lift
data lambda lfn rtv report independ nih data
pt assess w/ impress w/ undetect rna achiev bloq
median declin log achiev log declin hdv rna end-of-treat
data pt like report importantli combo treatment
well toler believ ph ii lift triple-combo data aasld direct read
de-risk on-going ph iii d-livr trial hdv ph iii d-livr enrol
process across site countri target pt lona progeria
recap lona data show surviv improv progeria --
pre-nda pre-maa mtg w/ fda ema plan submit
nda on-track avexatid co mtg
on-going discuss w/ fda ph iii trial option -- come also
disclos file new indic congenit hyperinsulin chi
avexatid ultra-rar pediatr metabol genet disord estimate /eu
mention acquir exclus licens upenn children hospit
philadelphia chop avexitid antagonist
bph chi next meet lambda hdv like lift end-of-
treatment data potenti alt normal biopsi data submit nda lona
progeria
ptcl/ctcl readout -- key focu co given could rel fast
registr path market much interest cell therapi combo potenti w/
well solid tumor asset start dose clariti first plan
four cohort laser-focus registr ph ii w/ data expect
high/low expressor well ctcl note adcetri current
soc potenti price premium w/ implic
valuabl oppti note think broader w/ potenti target
lymphoma w/ combo w/ data strateg clariti
ask persist w/ nk cell tx approach remind dose
strategi includ initi combo mix subsequ dose also remain
interest baselin nk cell low vs high nk cell function excit
see other pay closer attent nk cell excit egfr
solid tumor given bispecif profil safeti efficaci demonstr extens
preclin data -- though dose escal includ all-com note potenti four
expans cohort includ krasmut kraswt lung krasmut
kraswt disclos note want go
see innat immun activ vs overexpress case indic
co mention bcma still move forward announc
pleas see import disclosur inform page report
start dose first pt w/ advanc preclin studi
interim efficaci high/low expressor efficaci data ctcl tmf
track two pivot readout ssc cf summer w/ lenabasum
management remain enthus w/ potenti nash/nafld early-stag preclin
pipelin progress well lena co recent present add data ole
ssc dm -- overal data seem in-lin w/ previou data cut
ssc ph iii baselin characterist disclos acr similar ph ii
help de-risk ph iii co said last patient-in
studi co report pivot data summer dm recal ph ii studi
includ pt amyopath skin involv ph iii
enrol broader moderate/sever pt w/ skin well muscl involv w/ activ
diseas -- ph iii readout expect cf co-announc enrol
complet trigger mileston cf foundat ph iib -- reduct
exacerb primari endpt trial mention dose
last pt recent -- w/ mo studi durat mo data lock-down analysi
track report pivot data summer crsp concern
lose pt trial tripl combo mention pt
dose pivot trial abl deliv data
co overcom hurdl formul compound reiter
import safeti regard brain penetr seen w/ rimonab co
track begin ph dose hv nih test pt w/ metabol syndrome/
nafld/nash demonstr biolog activ pt ph safeti profil
accept regard partnership mention well equip identifi
commerci compound target ec address rare inflammatori indic
howev broader indic may need help would will partner esp
w/ big pharma get increasingli interest space seen w/ recent
develop takeda roch next top-lin ph iii
data ssc ph iib data cf top-lin ph ii data sle initi ph sad/mad
complet lena dm ph iii enrol top-lin ph iii dm data
srra offici launch ph iii momentum trial myelofibrosi mf co believ
mmb anemia benefit vs rux detriment key differenti -- co confid enrol
timelin recent financ remov overhang essenti free stock
co highlight compar spleen/symptom improv demonstr head-
td ti benefit provid intrigu valu proposit srra start mmb
ph iii mf in-lin w/ guidanc start srra emphas low bar
approv w/ secondari endpoint transfus independ anemia benefit
could set mmb apart posit note srra seem confid ph iii design
base extens experi w/ mmb abil submit regulatori packag
would includ wealth data three ph iii simplify-i momentum
highlight kols/sit involv prior mmb trial express enthusiasm
around benefit mmb provid discuss ph iii program prior
pleas see import disclosur inform page report
-- believ design favor path could get mmb market
short time frame market cap co cross goal line enter valuabl
market oppti co recent financ remov key overhang financ brought
qualiti investor srra simultan restructur mmb royalti agreement w/
give ownership lower royalti next post-hoc data
estimate momentum top-lin data estimate reg file mmb
pleas see import disclosur inform page report
javatar bluematrix com/sellside/disclosur action call
inform compani recommend
report pleas visit websit http //
mauri raycroft ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
mitchel kapoor certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi llc act financi advisor kite pharma kite sale compani
jefferi group llc make market secur adr
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr inc
jefferi group llc make market secur adr sierra oncolog
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
 within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic
within past twelv month client jefferi llc invest bank servic
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
 one affili within past twelv month
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
inc within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic inc
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
inc one affili
within past twelv month inc client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
inc within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic inc
pleas see import disclosur inform page report
within past twelv month inc client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
inc one affili within past twelv month
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
sierra oncolog within next three month
within past month jefferi group llc affili subsidiari receiv compens invest bank
servic sierra oncolog
within past twelv month sierra oncolog client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
sierra oncolog one affili within past twelv month
inform compani recommend
report pleas visit websit http //
javatar bluematrix com/sellside/disclosur action call
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
pleas see import disclosur inform page report
